Did you know that nearly 6 million intravitreal injections (IVIs) were performed in just 2016? This number has only continued to rise, as more patients seek effective treatments for eye conditions like neovascular age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. According to a study published in Retina, the demand for these injections has surged annually, highlighting their critical role in preserving vision.
Intravitreal injections, which deliver anti-VEGF agents directly into the eye, offer the benefit of maximizing the drug’s effect within the eye while minimizing any unwanted systemic exposure. With new options like Vabysmo and Eylea becoming available, ophthalmologists now have more choices for treating these eye conditions. But how do they compare? And how do doctors decide which treatment is best for their patients?
In this article, we’ll break down the key differences and similarities between Vabysmo vs Eylea, looking at their mechanisms of action, dosing schedules, clinical trial results, and safety profiles to help guide evidence-based treatment decisions.
Key Takeaways
- Vabysmo (faricimab) uses a dual-pathway mechanism, targeting both VEGF-A and Angiopoietin-2 (Ang-2), offering longer dosing intervals and improved vascular integrity for patients with neovascular AMD retinal diseases.
- Eylea (aflibercept) focuses on single-pathway VEGF inhibition, making it a more predictable treatment with a fixed dosing schedule, primarily for conditions like wet AMD and diabetic macular edema.
- Vabysmo allows for extended intervals up to 16 weeks, especially in responsive patients, with its half-life around 7.5 days. Eylea, on the other hand, is typically dosed every 8 weeks, but 12-week intervals may be considered off-label under a treat-and-extend protocol.
- Both drugs target VEGF-driven neovascularization, but Eylea has more established, predictable dosing. Vabysmo’s flexibility offers convenience for both patients and an ophthalmologist or healthcare provider.
- Common ocular side effects for both VEGF drugs include conjunctival hemorrhage and eye pain, while systemic adverse events such as arterial thromboembolic events require careful monitoring, especially in patients with cardiovascular risk factors.
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. If you’re looking to buy Eylea, contact Medica Depot’s sales representatives and they will guide you on how to do so. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
Mechanism of Action: Dual vs Single Pathway Targeting
Understanding the difference between dual-pathway and single-pathway inhibition is essential for choosing the most effective treatment for retinal vascular diseases. The choice between Vabysmo and Eylea depends on their mechanisms of action, as they target different angiogenic pathways in unique ways.
- Vabysmo: Introduces a dual-pathway approach, targeting both VEGF-A and Angiopoietin-2 (Ang-2). By neutralizing VEGF-A and blocking Ang-2, Vabysmo strengthens vascular integrity, which helps prevent abnormal blood vessel growth while improving the stability of the retinal vessels. This dual inhibition provides longer treatment durability and extends the time between injections, offering patients more flexibility in their treatment schedule.
- Eylea: Focuses on single-pathway VEGF inhibition. It acts as a decoy receptor for VEGF-A, VEGF-B, and PIGF, preventing these ligands from binding to endothelial receptors, thereby reducing vascular leakage and halting abnormal blood vessel growth. This mechanism also leads to significant anatomical improvements but with a more fixed treatment regimen compared to Vabysmo.
Understanding these mechanistic differences helps healthcare providers choose the right treatment based on a patient’s condition, treatment goals, and personal preferences for dosing intervals.
Indications and Clinical Use for Vabysmo and Eylea
In addition to their mechanistic differences, Vabysmo and Eylea are approved for different retinal diseases. Medical professionals need to evaluate patient characteristics, including the specific condition being treated, to decide which product is most suitable.
Vabysmo Indications
- Neovascular (wet) age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Macular edema secondary to retinal vein occlusion (branch and central)
Eylea Indications
- Neovascular (wet) AMD
- Retinopathy of prematurity (ROP)
- Diabetic retinopathy (DR)
- Macular edema secondary to retinal vein occlusion (RVO) and diabetic macular edema (DME)
Dosing Flexibility and Treatment Interval Comparison
Both Vabysmo and Eylea offer flexibility in dosing schedules, but the intervals and treatment protocols differ. Healthcare providers can personalize these schedules based on patient response, disease stability, and lifestyle preferences.
Vabysmo Dosing Schedule
Vabysmo’s dual-pathway inhibition offers more flexibility with longer intervals between injections. The typical treatment begins with four monthly 6mg injections to establish the desired therapeutic levels. After that, providers can adopt a treat-and-extend strategy, lengthening the injection interval by 2 weeks if vision and anatomical response remain stable.
In responsive patients, intervals may extend up to 16 weeks between injections, significantly reducing the number of visits. According to Vabysmo’s prescribing information, its half-life is approximately 7.5 days, supporting longer dosing intervals.
Eylea Dosing Schedule
Eylea follows a more predictable fixed-interval model, with three consecutive 2mg injections in the first three months. After this, the maintenance dose is typically 2mg every 8 weeks. However, under the treat-and-extend protocol, some practitioners may extend to 12-week intervals for patients showing sustained anatomical and functional stability—this extension is off-label and goes beyond the fixed 8-week regimen.
When patients ask, “How long does Eylea stay in your system?“, practitioners should explain that Eylea’s half-life is between 5 to 7 days, allowing for extended intervals when stable.
Safety Profiles and Anatomical Response Differences
While both Vabysmo and Eylea effectively treat VEGF-driven retinal diseases, they come with distinct safety profiles and vary in ocular versus systemic side effects. Understanding these can help clinicians optimize patient care, ensuring safe and effective treatment.
Ocular and Systemic Safety Profiles
The commonly reported ocular reactions of Vabysmo include:
- Conjunctival Hemorrhage
- Eye Pain
- Eye Irritation
- Ocular Discomfort
Its clinical information has also reported minimal systemic reactions that require prompt medical attention.
- Endophthalmitis and Retinal Detachments
- Increase in Intraocular Pressure
- Arterial Thromboembolic Events (e.g., nonfatal stroke, nonfatal myocardial infarction, or vascular death)
On the other hand, the common Eylea side effects post-treatment include:
- Conjunctival Hemorrhage
- Transient Eye Pain
- Blurred Vision
Like any other medications or treatments, Eylea may also trigger systemic side effects after an injection session. These reactions show in Eylea’s prescribing information:
- Increased Intraocular Pressure
- Cataract Formation
- Arterial Thromboembolic Events
Healthcare providers should always evaluate cardiovascular risk before treatment, as both drugs may trigger systemic adverse events like arterial thromboembolic events, which need careful consideration, particularly in patients with recent cardiovascular events.
Conclusion
When comparing Vabysmo and Eylea, it’s clear that both treatments offer highly effective solutions for retinal vascular diseases. Vabysmo‘s dual-pathway mechanism allows for longer intervals between injections, making it a convenient choice for patients. On the other hand, Eylea‘s predictable dosing schedule ensures stability in retinal conditions but has a more fixed regimen compared to Vabysmo.
Ultimately, the choice between these treatments depends on a variety of factors, including the disease type, patient preferences, and safety considerations. By understanding their differences and similarities, healthcare providers can make informed decisions to optimize outcomes and improve patient adherence.
FAQs
1. What is the main difference between Vabysmo and Eylea?
Vabysmo targets both VEGF and Ang-2, while Eylea focuses solely on VEGF. This difference affects their effectiveness and the frequency of patient injections.
2. How do the dosing schedules compare for Vabysmo and Eylea?
Vabysmo allows for extended intervals between injections, potentially up to 16 weeks. Eylea, on the other hand, follows a fixed schedule with injections every eight weeks after an initial series.
3. What conditions do Vabysmo and Eylea treat?
Both treatments are approved for conditions like neovascular age-related macular degeneration and diabetic macular edema. However, Eylea also treats retinopathy of prematurity and other specific visual impairments.
References
Chaturvedi R, Wannamaker KW, Riviere PJ, Khanani AM, Wykoff CC, Chao DL. Real-World Trends in Intravitreal Injection Practices among American Retina Specialists. Ophthalmol Retina. 2019;3(8):656-662. doi:10.1016/j.oret.2019.03.023
HIGHLIGHTS OF PRESCRIBING INFORMATION | VABYSMO® (faricimab-svoa). www.gene.com. Published 2022. Accessed August 1, 2025. https://www.gene.com/download/pdf/vabysmo_prescribing.pdf
